UNSPSC 51382003: Flunoxaprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H12FNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UKU5U19W9M, chemically known as 5-benzoxazoleacetic acid, 2-(4-fluorophenyl)-alpha-methyl-, (s)- but generally known as flunoxaprofen, which bears US NIH Compound Identifier 68869. European Medicines Agency schedules Flunoxaprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07713MIG.

UNSPSC 51382003 Flunoxaprofen is a Commodity-tier code nominally reserved for a single nonsteroidal anti-inflammatory drug product, but recent state and local solicitations show little activity directly aligned with this specific pharmaceutical. The recent opportunities posted under this code involve broader pharmaceutical procurement — naloxone (an opioid antagonist), generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs — rather than flunoxaprofen specifically. State and local governments issuing under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both single-jurisdiction purchasing and multistate collaborative arrangements designed to aggregate demand and negotiate volume pricing across participating entities.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multistate reach extending to Oregon and other cooperative members. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and MMCAP's S1070000015802 RFP (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers with contract effectiveness July 1, 2026. The code shows limited recent procurement activity specifically for flunoxaprofen; state and local agencies are instead using broader pharmaceutical commodity codes for larger-scale, multi-product purchasing programs.